欧林生物：2026年1月，董事及高管股份变动为回购注销而非二级市场减持

Core Viewpoint - The company clarified that the share changes by directors and executives in January 2026 are not due to secondary market sell-offs, but rather a repurchase and cancellation operation in accordance with the "2023 Restricted Stock Incentive Plan" [1] Group 1 - The company responded to investor inquiries on its interactive platform regarding share changes [1] - The repurchase and cancellation of shares are part of the implementation of the "2023 Restricted Stock Incentive Plan" [1] - The details of the share repurchase and cancellation were disclosed in the announcement dated January 10, 2026, with the announcement number 2026-002 [1]